STAT

Drug treatments didn’t work. Can a simple diet help change these children’s lives?

In an unconventional trial sponsored by wealthy benefactors, children with a rare disorder are treated to summer camp — but with some strings attached.

KISSIMMEE, Fla. — Twelve-year-old Cecily Vammino’s eyebrows shot up as she closed her lips around the veggie pie. It was a subtle mélange of carrots, potatoes, and zucchini, surrounded by a vaguely sweet crust, and it was not working for her.

Cecily’s jaw carefully dispatched the invader while her left hand slid the remaining threat to a place where it could not harm her.

“Uh-uh,” she said, shaking her head.

Like every other meal Cecily would be sharing with 19 other children and their parents this month, this one was freshly cooked and served by the crack staff of kitchen professionals who were working under strict orders: Give the kids anything they want, as long as it’s all organic, and free of gluten, dairy, salt, and processed sugar.

It was a grand medical — and, in ways, social — experiment. The children are all living with a rare kidney disorder called , or FSGS, in which their kidneys leak proteins into the bloodstream. The disease strikes 5,000 people in the United States each year, and for a

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Drug Shortages, Medicare Spending On An Alzheimer’s Drug, And More
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related Books & Audiobooks